Is there a place for incretin therapies in obesity and prediabetes?

Research output: Contribution to journal › Journal article › peer-review

Standard

Is there a place for incretin therapies in obesity and prediabetes? / Holst, Jens Juul; Deacon, Carolyn F.

In: Trends in Endocrinology and Metabolism, Vol. 24, No. 3, 13.02.2013, p. 145-152.

Research output: Contribution to journal › Journal article › peer-review

Harvard

Holst, JJ & Deacon, CF 2013, 'Is there a place for incretin therapies in obesity and prediabetes?', Trends in Endocrinology and Metabolism, vol. 24, no. 3, pp. 145-152. https://doi.org/10.1016/j.tem.2013.01.004

APA

Holst, J. J., & Deacon, C. F. (2013). Is there a place for incretin therapies in obesity and prediabetes? Trends in Endocrinology and Metabolism, 24(3), 145-152. https://doi.org/10.1016/j.tem.2013.01.004

Vancouver

Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends in Endocrinology and Metabolism. 2013 Feb 13;24(3):145-152. https://doi.org/10.1016/j.tem.2013.01.004

Author

Holst, Jens Juul ; Deacon, Carolyn F. / Is there a place for incretin therapies in obesity and prediabetes?. In: Trends in Endocrinology and Metabolism. 2013 ; Vol. 24, No. 3. pp. 145-152.

Bibtex

@article{e8a847ec55914ffa98c09525c6a91316,
title = "Is there a place for incretin therapies in obesity and prediabetes?",
abstract = "Incretin-based therapies exploit the insulinotropic actions of the gut hormones gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) for the treatment of diabetes and include GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates the incretin hormones in the body. Both drug classes improve metabolic control in type 2 diabetes (T2DM), with GLP-1 receptor agonists also lowering body weight. Pharmacotherapy using DPP-4 inhibitors has few side effects and is weight neutral. Animal studies support their use in prediabetes; however, human data are scarce. GLP-1 receptor agonist effects are also apparent in non-diabetic obese individuals. Therefore, incretin-based therapies, if safe, may be effective in preventing progression of prediabetes; and GLP-1 receptor agonists may have potential for use in the treatment of obesity.",
author = "Holst, {Jens Juul} and Deacon, {Carolyn F}",
note = "Copyright {\textcopyright} 2013 Elsevier Ltd. All rights reserved.",
year = "2013",
month = feb,
day = "13",
doi = "10.1016/j.tem.2013.01.004",
language = "English",
volume = "24",
pages = "145--152",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier Ltd. * Trends Journals",
number = "3",

}

RIS

TY - JOUR

T1 - Is there a place for incretin therapies in obesity and prediabetes?

AU - Holst, Jens Juul

AU - Deacon, Carolyn F

N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

PY - 2013/2/13

Y1 - 2013/2/13

N2 - Incretin-based therapies exploit the insulinotropic actions of the gut hormones gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) for the treatment of diabetes and include GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates the incretin hormones in the body. Both drug classes improve metabolic control in type 2 diabetes (T2DM), with GLP-1 receptor agonists also lowering body weight. Pharmacotherapy using DPP-4 inhibitors has few side effects and is weight neutral. Animal studies support their use in prediabetes; however, human data are scarce. GLP-1 receptor agonist effects are also apparent in non-diabetic obese individuals. Therefore, incretin-based therapies, if safe, may be effective in preventing progression of prediabetes; and GLP-1 receptor agonists may have potential for use in the treatment of obesity.

AB - Incretin-based therapies exploit the insulinotropic actions of the gut hormones gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) for the treatment of diabetes and include GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates the incretin hormones in the body. Both drug classes improve metabolic control in type 2 diabetes (T2DM), with GLP-1 receptor agonists also lowering body weight. Pharmacotherapy using DPP-4 inhibitors has few side effects and is weight neutral. Animal studies support their use in prediabetes; however, human data are scarce. GLP-1 receptor agonist effects are also apparent in non-diabetic obese individuals. Therefore, incretin-based therapies, if safe, may be effective in preventing progression of prediabetes; and GLP-1 receptor agonists may have potential for use in the treatment of obesity.

U2 - 10.1016/j.tem.2013.01.004

DO - 10.1016/j.tem.2013.01.004

M3 - Journal article

C2 - 23415157

VL - 24

SP - 145

EP - 152

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

SN - 1043-2760

IS - 3

ER -

ID: 45840221